Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes

被引：0
|
作者：
DeFronzo, R
Ratner, R
Han, J
Kim, D
Fineman, M
Baron, A
机构：
[1] Univ Texas, Hlth Sci Ctr, Diabet Div, San Antonio, TX USA
[2] George Washington Univ, Sch Med, Dept Med, Bethesda, MD USA
[3] Amylin Pharmaceut Inc, Clin Affairs, San Diego, CA USA
来源：
DIABETOLOGIA | 2004年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
775
引用
收藏
页码：A280 / A280
页数：1
相关论文
共 50 条
  • [21] 28 days of treatment with AC2993 (synthetic exendin-4) improved glycemic control in patients with Type 2 diabetes concomitantly treated with metformin (met) and/or sulfonylurea (sfu)
    Fineman, M
    Bicsak, T
    Shen, L
    Taylor, K
    Gaines, E
    Varns, A
    Kim, D
    Baron, A
    DIABETOLOGIA, 2002, 45 : A44 - A44
  • [22] Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes
    Henry, Robert R.
    Ratner, Robert E.
    Stonehouse, Anthony H.
    Guan, Xuesong
    Poon, Terri
    Malone, James K.
    Kim, Dennis D.
    Kendall, David M.
    DIABETES, 2006, 55 : A116 - A116
  • [23] Once-Weekly Exenatide Used for 6 Months Provided Both Improved Glycemic Control and Weight Loss Compared to Sitagliptin, Pioglitazone, or Insulin Glargine in Metformin-Treated Patients with Type 2 Diabetes
    Horton, Edward
    Taylor, Kristin
    Porter, T. K. Booker
    Han, Jenny
    Wilhelm, Ken
    Harris, Carmen
    DIABETES, 2010, 59 : A163 - A163
  • [24] Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study
    Zamani, Batool
    Tabatabizadeh, Seyyed Mashaalah
    Gilasi, Hamidreza
    Yazdani, Shadi
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2024, 44 (04) : 385 - 391
  • [25] Effects of exenatide on glycemic control and weight in patients with type 2 diabetes in clinical practice: the Nancy experience
    Groza, L.
    Guerci, B.
    Halter, C.
    Mohebbi, H.
    Ziegler, O.
    DIABETES & METABOLISM, 2011, 37 : A4 - A4
  • [26] Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes
    Rosenstock, J
    Brown, A
    Fischer, J
    Jain, A
    Littlejohn, T
    Nadeau, D
    Sussman, A
    Taylor, T
    Krol, A
    Magner, J
    DIABETES CARE, 1998, 21 (12) : 2050 - 2055
  • [27] Twenty-eight day dose-response study with exenatide (synthetic exendin-4) in subjects with type 2 diabetes treated with metformin or with diet and exercise
    Poon, TH
    Nelson, P
    Love, K
    Shen, L
    Bicsak, TA
    Taylor, K
    Kim, DD
    DIABETES, 2004, 53 : A142 - A142
  • [28] Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
    Kadowaki, Takashi
    Namba, Mitsuyoshi
    Yamamura, Ayuko
    Sowa, Hideaki
    Wolka, Anne M.
    Brodows, Robert G.
    ENDOCRINE JOURNAL, 2009, 56 (03) : 415 - 424
  • [29] Effect of alogliptin combined with pioglitazone on glycaemic control in metformin-treated patients with type 2 diabetes
    DeFronzo, R.
    Burant, C.
    Fleck, P.
    Wilson, C.
    Mekki, Q.
    Pratley, R.
    DIABETOLOGIA, 2009, 52 : S295 - S295
  • [30] Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy
    Karagianni, P.
    Polyzos, S. A.
    Kartali, N.
    Zografou, I
    Sambanis, C.
    ADVANCES IN MEDICAL SCIENCES, 2013, 58 (01): : 38 - 43
12345